[1]李柯 吴霞 邵加庆.基于胰高血糖素的糖尿病治疗药物研究进展[J].国际内分泌代谢杂志,2018,38(01):15-18.[doi:10.3760/cma.j.issn.1673-4157.2018.01.004]
　Li Ke*,Wu Xia,Shao Jiaqing. *.Research progress in the diabetic drugs based on glucagon[J].International Journal of Endocrinology and Metabolism,2018,38(01):15-18.[doi:10.3760/cma.j.issn.1673-4157.2018.01.004]
点击复制

基于胰高血糖素的糖尿病治疗药物研究进展()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
38
期数:
2018年01期
页码:
15-18
栏目:
综述
出版日期:
2018-01-20

文章信息/Info

Title:
Research progress in the diabetic drugs based on glucagon
作者:
李柯 吴霞 邵加庆
210002 南京,南方医科大学南京临床学院(解放军南京总医院)内分泌科(李柯、邵加庆); 210002 南京医科大学金陵临床学院(解放军南京总医院)内分泌科(吴霞)
Author(s):
Li Ke*;  Wu Xia;  Shao Jiaqing. *
Department of Endocrinology, Nanjing Clinical Institute of Southern Medical University, Nanjing 210002, China
关键词:
胰高血糖素;  胰高血糖素受体拮抗剂;  胰高血糖素受体激动剂
Keywords:
Glucagon;  Glucagon receptor antagonists;  Glucagon receptor agonists
DOI:
10.3760/cma.j.issn.1673-4157.2018.01.004
摘要:
基于胰高血糖素的糖尿病治疗药物中,内源性胰高血糖素能快速升高血糖,作为严重低血糖的急救药物应用于临床; 胰高血糖素受体拮抗剂的研发起源于糖尿病患者胰高血糖素的过度分泌,拮抗胰高血糖素的作用能降低患者血糖; 而胰高血糖素受体激动剂的研发则基于胰高血糖素升糖作用外的降脂及促进能量消耗作用,其与肠促胰素的双重受体激动剂能使肥胖的糖尿病患者进一步获益。虽然这些药物大多数尚处于临床前期的研究中,但在糖尿病治疗上,它们有望成为有效的降糖药物,将给糖尿病患者带来曙光。
Abstract:
Among these diabetic drugs based on glucagon, endogenous glucagon can rapidly increase blood glucose and is used as a first aid for severe hypoglycemia in clinic; the development of glucagon receptor antagonists is due to the hyperglucagon secretion in diabetic patients, anti-glucagon can lower blood glucose in diabetic patients; moreover, in addition to hyperglycemic effect, glucagon can also reduce blood lipid and promote energy consumption, which provides a theoretical basis for the research and development of glucagon receptor agonists, its dual receptor agonists with incretin can further benefit obese diabetic patients. Although most of these drugs are still in preclinical studies, they are expected to be effective drugs controlling blood glucose in the treatment of diabetes mellitus and bring hopes to patients with diabetes mellitus.

参考文献/References:


[1] Holst JJ,Wewer Albrechtsen NJ,Pedersen J,et al.Glucagon and amino acids are linked in a mutual feedback cycle: the liver-α-cell axis[J]. Diabetes,2017,66(2):235-240.DOI:10.2337/db16-0994.
[2] Kraft G,Coate KC,Winnick JJ,et al.Glucagon's effect on liver protein metabolism in vivo[J].Am J Physiol Endocrinol Metab,2017,313(3):E263-E272.DOI:10.1152/ajpendo.00045.2017.
[3] Patel V,Joharapurkar A,Kshirsagar S,et al. Central and peripheral glucagon reduces hyperlipidemia in rats and hamsters[J].Drug Res(Stuttg),2017,67(6):318-326. DOI:10.1055/s-0043-102405.
[4] Arafat AM,Kaczmarek P,Skrzypski M,et al.Glucagon regulates orexin A secretion in humans and rodents[J].Diabetologia,2014,57(10):2108-2116.DOI:10.1007/s00125-014-3335-4.
[5] Zhang H,Qiao A,Yang D,et al.Structure of the full-length glucagon class B G-protein-coupled receptor[J].Nature,2017,546(7657):259-264.DOI:10.1038/nature22363.
[6] Haymond MW,DuBose SN,Rickels MR,et al.Efficacy and safety of mini-dose glucagon for treatment of nonsevere hypoglycemia in adults with type 1 diabetes[J].J Clin Endocrinol Metab,2017,102(8):2994-3001.DOI:10.1210/jc.2017-00591.
[7] Grant JS,Graven LJ.Intranasal glucagon for severe hypoglycemia[J].Home Healthc Now,2017,35(2):114-115.DOI:10.1097/NHH.0000000000000495.
[8] Haidar A,Smaoui MR,Legault L,et al. The role of glucagon in the artificial pancreas[J].Lancet Diabetes Endocrinol,2016,4(6):476-479. DOI:10.1016/S2213-8587(16)30006-7.
[9] Ahrén B,Larsson H.Impaired glucose tolerance(IGT)is associated with reduced insulin-induced suppression of glucagon concentrations[J].Diabetologia,2001,44(11):1998-2003.DOI:10.1007/s001250100003.
[10] Song WJ,Mondal P,Wolfe A,et al. Glucagon regulates hepatic kisspeptin to impair insulin secretion[J].Cell Metab,2014,19(4):667-681.DOI:10.1016/j.cmet.2014.03.005.
[11] Knop FK,Aaboe K,Vilsbφll T,et al. Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity[J].Diabetes Obes Metab,2012,14(6):500-510.DOI:10.1111/j.1463-1326.2011.01549.x.
[12] Wang MY, Yan H, Shi Z,et al. Glucagon receptor antibody completely suppresses type 1 diabetes phenotype without insulin by disrupting a novel diabetogenic pathway[J].Proc Natl Acad Sci U S A,2015,112(8):2503-2508. DOI:10.1073/pnas.1424934112.
[13] Okamoto H,Kim J,Aglione J,et al.Glucagon receptor blockade with a human antibody normalizes blood glucose in diabetic mice and monkeys[J].Endocrinology,2015,156(8):2781-2794.DOI:10.1210/en.2015-1011.
[14] Lee Y,Wang MY,Du XQ,et al.Glucagon receptor knockout prevents insulin-deficient type 1 diabetes in mice[J].Diabetes,2011,60(2):391-397.DOI:10.2337/db10-0426.
[15] McShane LM,Franklin ZJ,O'Harte FP,et al. Ablation of glucagon receptor signaling by peptide-based glucagon antagonists improves glucose tolerance in high fat fed mice[J].Peptides,2014,60:95-101.DOI:10.1016/j.peptides.2014.08.002.
[16] Kazda CM,Ding Y,Kelly RP,et al.Evaluation of efficacy and safety of the glucagon receptor antagonist LY2409021 in patients with type 2 diabetes: 12- and 24-week phase 2 studies[J].Diabetes Care,2016,39(7):1241-1249.DOI:10.2337/dc15-1643.
[17] Kelly RP,Garhyan P,Raddad E,et al.Short-term administration of the glucagon receptor antagonist LY2409021 lowers blood glucose in healthy people and in those with type 2 diabetes[J].Diabetes Obes Metab,2015,17(4):414-422.DOI:10.1111/dom.12446.
[18] Kazda CM,Frias J,Foga I,et al.Treatment with the glucagon receptor antagonist LY2409021 increases ambulatory blood pressure in patients with type 2 diabetes[J].Diabetes Obes Metab,2017,19(8):1071-1077.DOI:10.1111/dom.12904.
[19] Guzman CB,Zhang XM,Liu R,et al.Treatment with LY2409021, a glucagon receptor antagonist, increases liver fat in patients with type 2 diabetes[J].Diabetes Obes Metab,2017,19(11):1521-1528.DOI:10.1111/dom.12958.
[20] Bergman A,Tan B,Somayaji VR,et al.A 4-week study assessing the pharmacokinetics, pharmacodynamics, safety, and tolerability of the glucagon receptor antagonist PF-06291874 administered as monotherapy in subjects with type 2 diabetes mellitus[J].Diabetes Res Clin Pract,2017,126:95-104. DOI:10.1016/j.diabres.2017.01.019.
[21] Vajda EG,Logan D,Lasseter K,et al.Pharmacokinetics and pharmacodynamics of single and multiple doses of the glucagon receptor antagonist LGD-6972 in healthy subjects and subjects with type 2 diabetes mellitus[J].Diabetes Obes Metab,2017,19(1):24-32.DOI:10.1111/dom.12752.
[22] Mani BK,Uchida A,Lee Y,et al.Hypoglycemic effect of combined ghrelin and glucagon receptor blockade[J].Diabetes,2017,66(7):1847-1857.DOI:10.2337/db16-1303.
[23] Okamoto H,Cavino K,Na E,et al.Glucagon receptor inhibition normalizes blood glucose in severe insulin-resistant mice[J].Proc Natl Acad Sci U S A,2017,114(10):2753-2758.DOI:10.1073/pnas.1621069114.
[24] McShane LM,Irwin N,O'Flynn D,et al.Glucagon receptor antagonist and GIP agonist combination for diet-induced obese mice[J].J Endocrinol,2016,229(3):319-330.DOI:10.1530/JOE-15-0463.
[25] Neumann UH,Ho JS,Mojibian M,et al.Glucagon receptor gene deletion in insulin knockout mice modestly reduces blood glucose and ketones but does not promote survival[J].Mol Metab,2016,5(8):731-736.DOI:10.1016/j.molmet.2016.05.014.
[26] Chakravarthy M,Parsons S,Lassman ME,et al.Effects of 13-hour hyperglucagonemia on energy expenditure and hepatic glucose production in humans[J].Diabetes,2017,66(1):36-44.DOI:10.2337/db16-0746.
[27] Lv S,Qiu X,Li J,et al.Glucagon-induced extracellular cAMP regulates hepatic lipid metabolism[J].J Endocrinol,2017,234(2):73-87.DOI:10.1530/JOE-16-0649.
[28] Henderson SJ,Konkar A,Hornigold DC,et al. Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates[J].Diabetes Obes Metab,2016,18(12):1176-1190.DOI:10.1111/dom.12735.
[29] Valdecantos MP,Pardo V,Ruiz L,et al.A novel glucagon-like peptide 1/glucagon receptor dual agonist improves steatohepatitis and liver regeneration in mice[J].Hepatology,2017,65(3):950-968.DOI:10.1002/hep.28962.
[30] Green AD,Vasu S,Moffett RC,et al.Co-culture of clonal beta cells with GLP-1 and glucagon-secreting cell line impacts on beta cell insulin secretion, proliferation and susceptibility to cytotoxins[J].Biochimie,2016,125:119-125.DOI:10.1016/j.biochi.2016.03.007.
[31] Scheen AJ,Paquot N.Obesity. A new paradigm for treating obesity and diabetes mellitus[J].Nat Rev Endocrinol,2015,11(4):196-198.DOI:10.1038/nrendo.2015.3.

备注/Memo

备注/Memo:
基金项目:国家自然科学基金(81471018)
通信作者:邵加庆, Email:shaojiaq@hotmail.com
更新日期/Last Update: 2018-01-30